shutterstock_1395147236_poptika

Poptika / Shutterstock.com

15 December 2020Big PharmaSally Shorthose and Rumana Khanom

What 2020 means for the life sciences

2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

COVID-19: Protection of IP for AI tools

1 September 2020 As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

After Brexit: new directions for clinical trials

10 October 2017 If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

More on this story

COVID-19: Protection of IP for AI tools

1 September 2020 As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

After Brexit: new directions for clinical trials

10 October 2017 If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

More on this story

COVID-19: Protection of IP for AI tools

1 September 2020 As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

After Brexit: new directions for clinical trials

10 October 2017 If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

More features

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team

AstraZeneca forced to clarify deal terms in row with university

Novartis loses cancer drug patent following Teva challenge at EPO